Compare · DXCM vs ICU
DXCM vs ICU
Side-by-side comparison of DexCom Inc. (DXCM) and SeaStar Medical Holding Corporation (ICU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and ICU operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.60B, about 1490.7x ICU ($19.2M).
- Over the past year, DXCM is down 12.6% and ICU is down 12.5% - ICU leads by 0.1 points.
- ICU has been more active in the news (11 items in the past 4 weeks vs 5 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for ICU).
- Company
- DexCom Inc.
- SeaStar Medical Holding Corporation
- Price
- $74.14-2.88%
- $4.87+1.46%
- Market cap
- $28.60B
- $19.2M
- 1M return
- -1.50%
- +78.39%
- 1Y return
- -12.56%
- -12.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
Latest ICU
- SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
- Chief Executive Officer Schlorff Eric was granted 10,288 shares, increasing direct ownership by 26% to 50,140 units (SEC Form 4)
- Chief Medical Officer Chung Kevin was granted 7,202 shares, increasing direct ownership by 35% to 28,021 units (SEC Form 4)
- Director Vincent Bernadette N was granted 4,000 shares, increasing direct ownership by 95% to 8,200 units (SEC Form 4)
- Director Neuman John was granted 4,000 shares, increasing direct ownership by 33% to 16,200 units (SEC Form 4)
- Director Van Heel Kenneth was granted 4,000 shares, increasing direct ownership by 50% to 11,940 units (SEC Form 4)
- Director Baird Jennifer A was granted 4,000 shares, increasing direct ownership by 60% to 10,620 units (SEC Form 4)
- SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update
- SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury